Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mucocutaneous Lymph Node Syndrome | 27 | 2024 | 536 | 7.250 |
Why?
|
Systemic Inflammatory Response Syndrome | 26 | 2024 | 621 | 4.150 |
Why?
|
Immunoglobulins, Intravenous | 17 | 2024 | 664 | 2.830 |
Why?
|
Coronary Aneurysm | 9 | 2024 | 232 | 2.480 |
Why?
|
Lupus Erythematosus, Systemic | 12 | 2024 | 2155 | 1.970 |
Why?
|
Rheumatology | 8 | 2023 | 615 | 1.340 |
Why?
|
Glucocorticoids | 11 | 2024 | 2161 | 1.170 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 5 | 2023 | 299 | 1.140 |
Why?
|
Macrophage Activation Syndrome | 6 | 2024 | 124 | 0.920 |
Why?
|
Immunomodulation | 4 | 2023 | 549 | 0.760 |
Why?
|
Child | 63 | 2024 | 80156 | 0.740 |
Why?
|
Insurance | 1 | 2022 | 113 | 0.710 |
Why?
|
Antirheumatic Agents | 6 | 2022 | 1372 | 0.690 |
Why?
|
Anti-Inflammatory Agents | 4 | 2014 | 1809 | 0.610 |
Why?
|
Arthritis, Rheumatoid | 3 | 2023 | 3763 | 0.600 |
Why?
|
Delayed Diagnosis | 2 | 2021 | 463 | 0.580 |
Why?
|
Critical Pathways | 1 | 2021 | 474 | 0.570 |
Why?
|
Risk Adjustment | 1 | 2021 | 600 | 0.570 |
Why?
|
Child, Preschool | 33 | 2024 | 42230 | 0.520 |
Why?
|
Connective Tissue Diseases | 3 | 2023 | 285 | 0.510 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2220 | 0.490 |
Why?
|
Rheumatic Diseases | 4 | 2024 | 649 | 0.480 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1881 | 0.480 |
Why?
|
Fever | 4 | 2023 | 1618 | 0.470 |
Why?
|
Hyperglycemia | 1 | 2022 | 1376 | 0.450 |
Why?
|
Vaccines | 1 | 2022 | 844 | 0.430 |
Why?
|
Injections, Intra-Articular | 1 | 2014 | 280 | 0.420 |
Why?
|
Infant | 23 | 2024 | 36192 | 0.400 |
Why?
|
Pneumonia, Viral | 4 | 2022 | 3206 | 0.390 |
Why?
|
Adolescent | 34 | 2024 | 88324 | 0.380 |
Why?
|
Musculoskeletal Diseases | 2 | 2023 | 598 | 0.380 |
Why?
|
Humans | 93 | 2024 | 761572 | 0.370 |
Why?
|
Prednisolone | 1 | 2012 | 326 | 0.370 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2319 | 0.370 |
Why?
|
Echocardiography | 3 | 2019 | 4989 | 0.360 |
Why?
|
Coronary Vessel Anomalies | 2 | 2020 | 307 | 0.350 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2629 | 0.350 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 2118 | 0.350 |
Why?
|
Decision Support Techniques | 2 | 2017 | 1998 | 0.350 |
Why?
|
Pandemics | 5 | 2024 | 8656 | 0.340 |
Why?
|
Kidney Failure, Chronic | 1 | 2022 | 2472 | 0.340 |
Why?
|
Retrospective Studies | 26 | 2024 | 80646 | 0.340 |
Why?
|
Pediatrics | 3 | 2021 | 3589 | 0.330 |
Why?
|
Immunoglobulins | 1 | 2012 | 852 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3086 | 0.310 |
Why?
|
Interferon Type I | 2 | 2023 | 562 | 0.300 |
Why?
|
Coronary Vessels | 2 | 2017 | 3096 | 0.300 |
Why?
|
Health Status Disparities | 3 | 2024 | 1852 | 0.290 |
Why?
|
Young Adult | 14 | 2024 | 59255 | 0.260 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4352 | 0.250 |
Why?
|
Male | 44 | 2024 | 360842 | 0.250 |
Why?
|
Female | 47 | 2024 | 392686 | 0.250 |
Why?
|
Mevalonate Kinase Deficiency | 1 | 2023 | 19 | 0.220 |
Why?
|
Chest Pain | 1 | 2010 | 1091 | 0.220 |
Why?
|
Hospitals, Pediatric | 3 | 2024 | 1860 | 0.220 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 6312 | 0.220 |
Why?
|
Sweet Syndrome | 1 | 2023 | 58 | 0.210 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9177 | 0.210 |
Why?
|
Meningitis, Aseptic | 1 | 2023 | 59 | 0.210 |
Why?
|
Diagnosis, Differential | 9 | 2021 | 12975 | 0.210 |
Why?
|
Hospitalization | 5 | 2021 | 10721 | 0.200 |
Why?
|
Immunosuppressive Agents | 5 | 2023 | 4176 | 0.200 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 244 | 0.200 |
Why?
|
Boston | 5 | 2024 | 9326 | 0.190 |
Why?
|
Interleukin-18 | 2 | 2020 | 250 | 0.190 |
Why?
|
Anxiety | 1 | 2016 | 4573 | 0.190 |
Why?
|
C-Reactive Protein | 7 | 2023 | 3826 | 0.190 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7879 | 0.180 |
Why?
|
Facial Hemiatrophy | 1 | 2020 | 24 | 0.180 |
Why?
|
Child, Hospitalized | 1 | 2022 | 182 | 0.180 |
Why?
|
Age of Onset | 4 | 2024 | 3306 | 0.180 |
Why?
|
Paris | 1 | 2020 | 41 | 0.180 |
Why?
|
Agammaglobulinemia | 1 | 2022 | 171 | 0.180 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 107 | 0.170 |
Why?
|
Logistic Models | 3 | 2021 | 13255 | 0.170 |
Why?
|
Panniculitis | 1 | 2020 | 45 | 0.170 |
Why?
|
Pulmonary Alveolar Proteinosis | 1 | 2020 | 41 | 0.170 |
Why?
|
Enteritis | 1 | 2021 | 162 | 0.170 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15843 | 0.160 |
Why?
|
Synovial Fluid | 1 | 2021 | 393 | 0.160 |
Why?
|
Erythema | 1 | 2020 | 262 | 0.160 |
Why?
|
Socioeconomic Factors | 3 | 2021 | 7827 | 0.160 |
Why?
|
France | 1 | 2020 | 497 | 0.160 |
Why?
|
Shock | 1 | 2021 | 314 | 0.160 |
Why?
|
Thrombophilia | 1 | 2021 | 305 | 0.160 |
Why?
|
Atrioventricular Block | 1 | 2020 | 133 | 0.160 |
Why?
|
Lung Diseases | 2 | 2023 | 1909 | 0.160 |
Why?
|
Length of Stay | 4 | 2020 | 6426 | 0.160 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 269 | 0.160 |
Why?
|
Prednisone | 1 | 2023 | 1563 | 0.160 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 422 | 0.150 |
Why?
|
Stroke Volume | 5 | 2023 | 5496 | 0.150 |
Why?
|
Eosinophilia | 1 | 2023 | 560 | 0.150 |
Why?
|
Cell Polarity | 1 | 2021 | 636 | 0.150 |
Why?
|
Opportunistic Infections | 1 | 2021 | 376 | 0.150 |
Why?
|
Ventricular Function, Left | 4 | 2023 | 3879 | 0.150 |
Why?
|
Risk Factors | 14 | 2024 | 74213 | 0.150 |
Why?
|
Adenosine Deaminase | 1 | 2019 | 251 | 0.140 |
Why?
|
Syndrome | 2 | 2021 | 3267 | 0.140 |
Why?
|
Treatment Failure | 1 | 2023 | 2644 | 0.140 |
Why?
|
Depression | 1 | 2016 | 8124 | 0.130 |
Why?
|
Aftercare | 1 | 2022 | 914 | 0.130 |
Why?
|
Bacterial Infections | 2 | 2021 | 1391 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1126 | 0.130 |
Why?
|
Blood Coagulation | 1 | 2021 | 1154 | 0.120 |
Why?
|
Patient Transfer | 1 | 2022 | 794 | 0.120 |
Why?
|
Focus Groups | 1 | 2021 | 1413 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1175 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2023 | 64684 | 0.120 |
Why?
|
California | 1 | 2019 | 1430 | 0.120 |
Why?
|
Minority Groups | 1 | 2022 | 1203 | 0.120 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 934 | 0.120 |
Why?
|
Risk Assessment | 4 | 2021 | 23996 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.120 |
Why?
|
Infertility | 1 | 2021 | 654 | 0.110 |
Why?
|
Biological Products | 1 | 2023 | 914 | 0.110 |
Why?
|
Prognosis | 3 | 2021 | 29629 | 0.110 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15266 | 0.110 |
Why?
|
United States | 12 | 2024 | 72335 | 0.110 |
Why?
|
Triamcinolone Acetonide | 1 | 2014 | 100 | 0.110 |
Why?
|
Propensity Score | 1 | 2021 | 1913 | 0.110 |
Why?
|
North America | 1 | 2017 | 1276 | 0.110 |
Why?
|
Japan | 1 | 2018 | 1378 | 0.110 |
Why?
|
Psoriasis | 1 | 2022 | 950 | 0.110 |
Why?
|
Th17 Cells | 1 | 2020 | 794 | 0.110 |
Why?
|
Singapore | 1 | 2014 | 292 | 0.110 |
Why?
|
Age Factors | 3 | 2021 | 18398 | 0.110 |
Why?
|
Counseling | 1 | 2021 | 1547 | 0.110 |
Why?
|
Pleurisy | 1 | 2013 | 54 | 0.100 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2023 | 3080 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1256 | 0.100 |
Why?
|
Immunologic Factors | 2 | 2021 | 1589 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2022 | 3688 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2019 | 1651 | 0.100 |
Why?
|
Patient Discharge | 2 | 2022 | 3443 | 0.100 |
Why?
|
Weight Gain | 1 | 2022 | 2348 | 0.100 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6403 | 0.100 |
Why?
|
Laryngeal Diseases | 1 | 2015 | 243 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1723 | 0.100 |
Why?
|
Registries | 3 | 2023 | 8224 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8528 | 0.090 |
Why?
|
Massachusetts | 2 | 2021 | 8830 | 0.090 |
Why?
|
Hepatomegaly | 1 | 2010 | 84 | 0.090 |
Why?
|
Interleukin-6 | 1 | 2020 | 3208 | 0.090 |
Why?
|
Decision Support Systems, Clinical | 1 | 2020 | 1175 | 0.090 |
Why?
|
Larynx | 1 | 2015 | 492 | 0.090 |
Why?
|
Respiratory Tract Diseases | 1 | 2016 | 750 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1667 | 0.090 |
Why?
|
Qualitative Research | 1 | 2021 | 3023 | 0.090 |
Why?
|
Prospective Studies | 5 | 2023 | 54426 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 2004 | 0.090 |
Why?
|
Aspirin | 2 | 2021 | 3133 | 0.090 |
Why?
|
Inflammation | 5 | 2023 | 10773 | 0.090 |
Why?
|
Sarcoidosis | 1 | 2015 | 521 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2021 | 2775 | 0.080 |
Why?
|
Disease Progression | 3 | 2023 | 13510 | 0.080 |
Why?
|
Medication Adherence | 1 | 2021 | 2176 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3156 | 0.080 |
Why?
|
Pilot Projects | 1 | 2022 | 8633 | 0.080 |
Why?
|
Dilatation, Pathologic | 1 | 2010 | 527 | 0.080 |
Why?
|
Retreatment | 1 | 2010 | 598 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2422 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3384 | 0.080 |
Why?
|
Cohort Studies | 3 | 2023 | 41493 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3358 | 0.080 |
Why?
|
Heart | 1 | 2021 | 4404 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2273 | 0.070 |
Why?
|
Adult | 11 | 2024 | 221203 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2244 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4671 | 0.070 |
Why?
|
Heart Diseases | 1 | 2020 | 2781 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2022 | 10194 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2023 | 22176 | 0.070 |
Why?
|
Delphi Technique | 2 | 2021 | 846 | 0.070 |
Why?
|
Quality Improvement | 1 | 2021 | 3801 | 0.060 |
Why?
|
Immunoglobulin G | 2 | 2020 | 4544 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2021 | 4481 | 0.060 |
Why?
|
Blood Sedimentation | 2 | 2019 | 235 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1347 | 0.060 |
Why?
|
Physical Examination | 1 | 2010 | 1255 | 0.060 |
Why?
|
Chicago | 1 | 2024 | 254 | 0.060 |
Why?
|
Infant, Newborn | 4 | 2023 | 26198 | 0.060 |
Why?
|
Critical Care | 3 | 2021 | 2697 | 0.060 |
Why?
|
Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
Software | 1 | 2016 | 4434 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10212 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 602 | 0.050 |
Why?
|
Crowding | 1 | 2023 | 142 | 0.050 |
Why?
|
Diagnostic Errors | 2 | 2021 | 1265 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13367 | 0.050 |
Why?
|
Running | 1 | 2006 | 488 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20099 | 0.050 |
Why?
|
Lymphadenitis | 1 | 2021 | 99 | 0.040 |
Why?
|
Pain Measurement | 1 | 2010 | 3551 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39107 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4484 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12059 | 0.040 |
Why?
|
Subcutaneous Tissue | 1 | 2020 | 132 | 0.040 |
Why?
|
Conjunctivitis | 1 | 2021 | 155 | 0.040 |
Why?
|
Facial Muscles | 1 | 2020 | 159 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 322 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2023 | 496 | 0.040 |
Why?
|
Discriminant Analysis | 1 | 2020 | 223 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2013 | 5293 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2019 | 135 | 0.040 |
Why?
|
Patient Readmission | 1 | 2013 | 3271 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17904 | 0.040 |
Why?
|
Interleukin-1 | 1 | 2023 | 1248 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14032 | 0.040 |
Why?
|
Thrombelastography | 1 | 2021 | 187 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 778 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4580 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2021 | 432 | 0.040 |
Why?
|
Platelet Count | 1 | 2021 | 781 | 0.040 |
Why?
|
Databases, Factual | 1 | 2013 | 7967 | 0.040 |
Why?
|
Family Characteristics | 1 | 2023 | 1004 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 912 | 0.040 |
Why?
|
Cytokines | 2 | 2023 | 7396 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2021 | 1596 | 0.040 |
Why?
|
Bacteriophages | 1 | 2020 | 378 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2023 | 974 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36429 | 0.030 |
Why?
|
Ferritins | 1 | 2019 | 598 | 0.030 |
Why?
|
Advisory Committees | 1 | 2021 | 787 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1869 | 0.030 |
Why?
|
Dermatomyositis | 1 | 2019 | 258 | 0.030 |
Why?
|
Th1 Cells | 1 | 2021 | 1036 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1567 | 0.030 |
Why?
|
Anticoagulants | 2 | 2021 | 4812 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2418 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 30054 | 0.030 |
Why?
|
Hypotension | 1 | 2021 | 879 | 0.030 |
Why?
|
Virus Diseases | 1 | 2021 | 718 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1719 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2021 | 802 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2021 | 1071 | 0.030 |
Why?
|
Face | 1 | 2020 | 1026 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14666 | 0.030 |
Why?
|
Lung | 1 | 2013 | 10002 | 0.030 |
Why?
|
Autoantibodies | 1 | 2023 | 2116 | 0.030 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2021 | 1017 | 0.030 |
Why?
|
Biopsy | 2 | 2016 | 6766 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2020 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5247 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1459 | 0.030 |
Why?
|
Reference Values | 1 | 2019 | 4920 | 0.030 |
Why?
|
Regression Analysis | 1 | 2021 | 6344 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2022 | 1940 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7237 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3123 | 0.020 |
Why?
|
Blood Platelets | 1 | 2021 | 2479 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2016 | 707 | 0.020 |
Why?
|
Biomedical Research | 1 | 2006 | 3429 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3205 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2450 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3848 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9646 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2023 | 4758 | 0.020 |
Why?
|
Glycosylation | 1 | 2012 | 1097 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2094 | 0.020 |
Why?
|
Joints | 1 | 2011 | 322 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5872 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2630 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 2751 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4369 | 0.020 |
Why?
|
Middle Aged | 2 | 2021 | 220920 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3767 | 0.020 |
Why?
|
Aged | 1 | 2021 | 169310 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3060 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1682 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4399 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 6180 | 0.020 |
Why?
|
Internship and Residency | 1 | 2006 | 5882 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21355 | 0.010 |
Why?
|
International Cooperation | 1 | 2011 | 1422 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26127 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3530 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|